全文获取类型
收费全文 | 10753篇 |
免费 | 340篇 |
国内免费 | 31篇 |
专业分类
耳鼻咽喉 | 150篇 |
儿科学 | 170篇 |
妇产科学 | 294篇 |
基础医学 | 2134篇 |
口腔科学 | 211篇 |
临床医学 | 541篇 |
内科学 | 1009篇 |
皮肤病学 | 404篇 |
神经病学 | 867篇 |
特种医学 | 1542篇 |
外科学 | 1466篇 |
综合类 | 47篇 |
预防医学 | 748篇 |
眼科学 | 82篇 |
药学 | 1069篇 |
中国医学 | 90篇 |
肿瘤学 | 300篇 |
出版年
2023年 | 35篇 |
2022年 | 25篇 |
2021年 | 52篇 |
2020年 | 44篇 |
2019年 | 63篇 |
2018年 | 198篇 |
2017年 | 130篇 |
2016年 | 182篇 |
2015年 | 121篇 |
2014年 | 224篇 |
2013年 | 373篇 |
2012年 | 716篇 |
2011年 | 1075篇 |
2010年 | 473篇 |
2009年 | 162篇 |
2008年 | 761篇 |
2007年 | 936篇 |
2006年 | 907篇 |
2005年 | 724篇 |
2004年 | 650篇 |
2003年 | 654篇 |
2002年 | 569篇 |
2001年 | 368篇 |
2000年 | 478篇 |
1999年 | 262篇 |
1998年 | 74篇 |
1997年 | 51篇 |
1996年 | 33篇 |
1995年 | 44篇 |
1994年 | 23篇 |
1993年 | 18篇 |
1992年 | 19篇 |
1991年 | 22篇 |
1990年 | 28篇 |
1989年 | 21篇 |
1988年 | 24篇 |
1986年 | 18篇 |
1985年 | 30篇 |
1984年 | 22篇 |
1983年 | 22篇 |
1982年 | 29篇 |
1981年 | 29篇 |
1980年 | 29篇 |
1979年 | 27篇 |
1978年 | 28篇 |
1976年 | 19篇 |
1975年 | 26篇 |
1974年 | 18篇 |
1973年 | 18篇 |
1963年 | 19篇 |
排序方式: 共有10000条查询结果,搜索用时 858 毫秒
101.
102.
103.
Smigovec E Tripković B Sulentić M Smigovec I Haspl M 《Acta medica Croatica : c?asopis Hravatske akademije medicinskih znanosti》2001,55(4-5):211-214
The occurrence of pulmonary embolism, in spite of thromboprophylaxis after a minor elective orthopedic surgery (release of m. rectus femoris tendon) is reported. In case of this severe complication, an early diagnosis is of outmost importance to enable optimal therapy introduction. Deep vein thrombosis and pulmonary embolism are frequent complications after total joint replacement, however, they may also develop after minor surgical orthopedic procedures. The possible causes of pulmonary embolism after release of m. rectus femoris tendon included the history of varicose veins and sclerozation of calf veins, and operative procedure with intraoperative pressure upon large veins of the iliofemoral region, which may and is expected to occur during this procedure. The importance of thrombopropylaxis in orthopedic surgical procedures is emphasized by this case presentation. 相似文献
104.
105.
In this paper a gait efficiency assessment method, Gait Energy Efficiency Index (GEEI), which can be used in evaluation of the progress of the rehabilitation process in disabled persons, is proposed and described. The method is based on calculation of cross correlation between normalized time courses of kinetic and potential energy of the body's centre of mass (COM). We hypothesized that GEEI in energetically optimal normal walking should be high and invariable of gait speed. The method was tested on twelve healthy subjects walking at three different speeds and contrasted to five established gait energy consumption assessment methods. The results showed that GEEI in normal walking is close to 1 regardless of walking speed. 相似文献
106.
107.
Sertić J Cvitković P Myers A Saiki RK Stavljenić Rukavina A 《Croatian medical journal》2001,42(4):416-420
Today, approximately 15% of couples have reduced fertility. In most cases the reason is male infertility, usually of genetic origin. Thus, in the context of research in genes involved in reproduction and sex determination, genetic defects in gametogenesis are being extensively studied. The most frequent pathogenic causes of male infertility are Y chromosomal microdeletions and obstructive azoospermia due to congenital absence of the vas deferens (CAVD) in the presence of mutations in the cystic fibrosis transmembrane conductance regulator (CFTR) gene. We have investigated the most common CFTR gene alterations in Croatian men with CAVD, using Roche research prototype assays. Results revealed that the 5T variant was present in 27% of the subjects. The F508 deletion was found in 21% of the subjects. It was the most frequent mutation, although its incidence was much lower than among patients with cystic fibrosis. The prevalence of microdeletions in the azoospermia factor region (AZF) of the Y chromosome in Croatia was 4.5%. This is the first report of Y microdeletions in the Croatian population. Genetic counseling of all couples with the diagnosis of male infertility is recommended before intrauterine insemination, in vitro fertilization, and intracytoplasmic sperm injection, and should also include AZF and CFTR genotyping. Couples requesting assisted reproductive treatment should be offered molecular analysis of the CFTR gene, if male infertility due to obstructive azoospermia is the underlying cause. Also, men with severe oligozoospermia or non-obstructive azoospermia seeking assisted reproductive treatment should be screened for deletions in the Y chromosome. 相似文献
108.
109.
Jovanović I Stefanović N Antić S Ugrenović S Djindjić B Vidović N 《Italian journal of anatomy and embryology = Archivio italiano di anatomia ed embriologia》2004,109(1):19-33
Psammoma bodies are one of many choroid plexus aging changes which origin is still enigma for the scientists. During our investigation psammoma bodies were studied on 30 postmortem brains by light microscopy. They stained red with HE, and were PAS and AB PAS positive. The largest number of lamellas were stained blue with Mallory's connective tissue stain, except peripheral and next to the center lamella which stained red. During the aging, psammoma bodies became larger and more irregular, which was followed with group area and perimeter, single psammoma body average area and average perimeter, average diameter and contour index increase. Psammoma bodies mearged in the second and the third age group and mearging process led to larger and more irregular structures formation. The results of this investigation suggest that psammoma bodies are more frequent in choroid plexus of healthy older people and during the aging they obtain larger dimensions, more irregular contours, which is the result of their mutual mearging. 相似文献
110.
Fumić K Stavljenić-Rukavina A Mrsić M Potocki K 《Acta medica Croatica : c?asopis Hravatske akademije medicinskih znanosti》2004,58(5):353-358
Gaucher's disease is the most common lysosomal storage disorder. It was identified in 1882 by Phillipe Gaucher, a French dermatologist. However, it was not until 1965 that Gaucher disease was found to be due to a deficiency in the enzyme glucocerebrosidase (EC 3.2.1.45) which breaks down glucocerebroside, a cell membrane component. The deficiency in this enzyme leads to an accumulation of glucocerebroside within the lysosomes of macrophages throughout the body. Gaucher's disease is classified into three types: type 1 (non-neuronopathic), type 2 (acute neuronopathic), and type 3 (subacute neuronopathic). Of the three, type 1 is the most common, affecting one in 40,000-200,000 people and having a high prevalence among Ashkenazi Jews, affecting one in 450-1500. The signs and symptoms of type 1 disease demonstrate marked heterogeneity, from asymptomatic or mildly symptomatic, to severe disability with disfigurement and even death. Hepatosplenomegaly and thrombocytopenia are well documented. Less well-recognized are often insidious skeletal complications which affect the majority of type 1 patients and which are its most debilitating feature. In addition to clinical suspicion, some morphologic, hematologic and biochemical indicators can help establish the diagnosis. However, definitive diagnosis is only made by determining the catalytic activity of the lysosomal enzyme glucocerebrosidase. Confirmation of heterozygosity requires the use of molecular biotechnology methods. About 150 mutations of the glucocerebrosidase gene have been identified in patients with Gaucher's disease, some of which are predictive of phenotype. The history of treatment of Gaucher disease started with splenectomy and continued with bone marrow transplantation, before the recent introduction of safe and effective enzyme replacement therapy. In Croatia, nine patients with type 1 Gaucher's disease have been identified so far. Seven patients are on enzyme replacement therapy, and past results demonstrated significant improvement in all clinical symptoms, without development of any side effects. However, new treatments, such as substrate balance therapy and gene therapy, may become available within the next few years. The place, if any, that such therapies will have in the treatment of patients with Gaucher's disease will be dependent on the results of clinical studies currently in progress. 相似文献